A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels.
AuthorKruse, Robert L
Bloch, Evan M
Tobian, Aaron A R
Wang, Zack Z
JournalJournal of Clinical Microbiology
PublisherAmerican Society for Microbiology
MetadataShow full item record
AbstractSerologic point-of-care tests to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are an important tool in the COVID-19 pandemic. The majority of current point-of-care antibody tests developed for SARS-CoV-2 rely on lateral flow assays, but these do not offer quantitative information. To address this, we developed a novel antibody test leveraging hemagglutination, employing a dry card format currently used for typing ABO blood groups. Two hundred COVID-19 patient and 200 control plasma samples were reconstituted with O-negative red blood cells (RBCs) to form whole blood and added to dried viral-antibody fusion protein, followed by a stirring step and a tilting step, 3-min incubation, and a second tilting step. The sensitivities of the hemagglutination test, Euroimmun IgG enzyme-linked immunosorbent assay (ELISA), and receptor binding domain (RBD)-based CoronaChek lateral flow assay were 87.0%, 86.5%, and 84.5%, respectively, using samples obtained from recovered COVID-19 individuals. Testing prepandemic samples, the hemagglutination test had a specificity of 95.5%, compared to 97.3% and 98.9% for the ELISA and CoronaChek, respectively. A distribution of agglutination strengths was observed in COVID-19 convalescent-phase plasma samples, with the highest agglutination score (4) exhibiting significantly higher neutralizing antibody titers than weak positives (2) (P < 0.0001). Strong agglutinations were observed within 1 min of testing, and this shorter assay time also increased specificity to 98.5%. In conclusion, we developed a novel rapid, point-of-care RBC agglutination test for the detection of SARS-CoV-2 antibodies that can yield semiquantitative information on neutralizing antibody titer in patients. The 5-min test may find use in determination of serostatus prior to vaccination, postvaccination surveillance, and travel screening.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17644
- A hemagglutination-based, semi-quantitative test for point-of-care determination of SARS-CoV-2 antibody levels.
- Authors: Kruse RL, Huang Y, Lee A, Zhu X, Shrestha R, Laeyendecker O, Littlefield K, Pekosz A, Bloch EM, Tobian AAR, Wang ZZ
- Issue date: 2021 May 4
- A rapid, point-of-care red blood cell agglutination assay detecting antibodies against SARS-CoV-2.
- Authors: Kruse RL, Huang Y, Smetana H, Gehrie EA, Amukele TK, Tobian AAR, Mostafa HH, Wang ZZ
- Issue date: 2021 May 14
- Efficient Identification of High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method.
- Authors: Nguyen KD, Wirz OF, Röltgen K, Pandey S, Tolentino L, Boyd SD, Pham TD
- Issue date: 2021 Oct 1
- Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts.
- Authors: Bortz RH 3rd, Florez C, Laudermilch E, Wirchnianski AS, Lasso G, Malonis RJ, Georgiev GI, Vergnolle O, Herrera NG, Morano NC, Campbell ST, Orner EP, Mengotto A, Dieterle ME, Fels JM, Haslwanter D, Jangra RK, Celikgil A, Kimmel D, Lee JH, Mariano MC, Nakouzi A, Quiroz J, Rivera J, Szymczak WA, Tong K, Barnhill J, Forsell MNE, Ahlm C, Stein DT, Pirofski LA, Goldstein DY, Garforth SJ, Almo SC, Daily JP, Prystowsky MB, Faix JD, Fox AS, Weiss LM, Lai JR, Chandran K
- Issue date: 2021 Apr 21
- Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
- Authors: Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W, George PJ, Rodriguez M, Tricoche N, Schmidt F, Gao C, Jawahar S, Pal M, Schnall E, Zhang H, Strauss D, Yazdanbakhsh K, Hillyer CD, Bieniasz PD, Hatziioannou T
- Issue date: 2020 Nov 18